Oruka Therapeutics (NASDAQ: ORKA) experienced a significant surge in its stock price on Monday, following the release of promising interim data from its Phase 2a clinical trial for its investigational psoriasis treatment, ORKA-001. The biotech firm also announced plans to raise $500 million through a public offering, capitalizing on the positive market sentiment.
Impressive Clinical Data
The EVERLAST-A trial results showed that 63.5% of patients treated with ORKA-001 achieved complete skin clearance, as measured by the Psoriasis Area and Severity Index (PASI 100), at 16 weeks. This compares to just one patient in the placebo group achieving similar results. Additionally, 82.5% of patients achieved at least a 90% improvement in their skin condition (PASI 90), and 84.1% were rated as clear or nearly clear on the Investigator Global Assessment scale.
Safety Profile
The drug demonstrated a favorable safety profile, with no serious adverse events reported in the treatment group. Treatment-emergent adverse events occurred in 50.8% of ORKA-001 recipients, compared to 57.1% in the placebo group, and no patients discontinued due to side effects.
Market Reaction and Financing
Shares of Oruka Therapeutics initially soared to an intraday high of $114.49 before settling at $76.39, still up approximately 10.5% from the previous close. Trading volume was heavy, exceeding 6.8 million shares. The company later announced a $500 million public offering, with underwriters having an option to purchase an additional $75 million in shares. The offering includes both common stock and pre-funded warrants.
Analyst Commentary
Analysts were largely bullish on the data. Barclays noted a best-in-class profile, citing numerical superiority over AbbVie's Skyrizi and results comparable to UCB's Bimzelx, though direct comparisons were not made. Jefferies analysts described the results as an "outright win over Skyrizi," projecting potential sales in the $5 billion to $10 billion range if the profile holds. Oruka CEO Lawrence Klein suggested the data could represent a "category-winning profile."
Long-Acting Potential
ORKA-001 is a monoclonal antibody targeting IL-23p19, a key immune signal in psoriasis. It is designed as a long-acting injectable, potentially requiring only one or two doses per year. The company reported that after a single 600 mg dose, drug concentrations remained above the desired trough for 52 weeks, supporting the possibility of annual dosing.
Future Milestones
Oruka plans to release longer-term data, including Week 28 efficacy and 52-week follow-up results, in the second half of 2026. The next phase, EVERLAST-B (Phase 2b), is expected to deliver data in 2027. However, the company cautioned that the financing's timing, size, and terms remain subject to market conditions, and dilution concerns could weigh on shares if the offering is priced below current levels.
The clinical trial, which enrolled 84 patients, is still in its early stages, and larger pivotal studies will be required for regulatory approval. Oruka's stock performance will likely hinge on upcoming data and the successful execution of its financing plans.
